Effect of the APOE4 Genotype on the Cerebrospinal Fluid Amyloid-beta and Tau Levels in Veterans with Traumatic Brain Injury 4234

Thursday, October 30, 2025

10:45 AM - 11:00 AM

Location: ROOM: Continental Ballroom B DIRECTIONS: Lobby Level: From the Main Elevator Bank, proceed right toward the FedEx Office. At the Fed Ex Office, turn right and proceed past the ACRM Registration Desk and into the Continental Foyer. Continental B Lobby is directly adjacent to the center section of the Continental Ballroom.

Author(s)

Amrutha Bindu Nagella, MBBS, MD (she/her/hers)

Research Scientist
Rehabilation Sciences, School of Public Health and Health Professions, University at Buffalo
Buffalo, NY, United States

Slides Slides
Michelle Eliason, MS, OTR/L

Occupational Therapist and PhD Student
University at Buffalo
Amherst, NY, United States
SL

Stacey C. Li

Medical Student
Jacobs School Of Medicine And Biomedical Sciences
Buffalo, New York, United States
Ghazala T. Saleem, EdD, MS, OTR/L (she/her/hers)

Assistant Professor
SUNY Buffalo
Buffalo, New York, United States

This presentation explores the interplay between APOE4 genotype and traumatic brain injury in influencing cerebrospinal fluid biomarker levels (Aβ42 and p-tau) associated with Alzheimer’s disease. Using data from the ADNI-DOD cohort, we examine how the co-occurrence of these risk factors affects amyloid-beta and tau pathology, highlighting the heightened vulnerability in ageing Veterans with both APOE4 positivity and TBI history. Findings of this study underscore the importance of targeted monitoring and the need for early intervention in this high-risk population.

Learning Objectives:

Recognise the importance of predisposing genetic risk factors in assessing the risk for the development of neurodegenerative conditions of the brain.
Identify that TBI alone may not be a significant risk factor for the development of Alzheimer’s disease.
Recognise the aggravated risk of Alzheimer’s pathophysiological process in patients with APOE4 genotype and history of TBI, prioritising the need for enhanced focus for early diagnosis, treatment and rehabilitation in this high-risk cohort.